ARTICLE | Product Development
Gilead holds back critical value-defining data in TROPiCS-02 news
Without PFS data, Gilead’s Trodelvy readout leaves the HR-positive, HER2-negative breast cancer market up for grabs
March 8, 2022 12:35 AM UTC
Gilead’s announcement that Trodelvy met the primary endpoint in a Phase III breast cancer trial, without reporting the data, didn’t bring investors much closer to understanding where the ADC will fit in the market for the drug’s most important indication.
On Monday, Gilead Sciences Inc. (NASDAQ:GILD) said Trodelvy sacituzumab govitecan-hziy, an ADC targeting TROP2, met the primary progression-free survival (PFS) endpoint in the Phase III TROPiCS-02 study treating HR-positive, HER2-negative breast cancer. The company also said there was a trend toward improvement in overall survival in the study...